[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Doric Nimrod Air One Limited LSE:DNA London Ordinary Share GG00B4MF3899 ORD PRF SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.54% 32.00 30.00 34.00 33.10 32.00 32.50 63,675 09:00:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -13.8 -32.4 - 14

Doric Nimrod Air One Share Discussion Threads

Showing 76 to 88 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
10/1/2007
08:16
US Supreme Court supports MedImmune's position in patent dispute with Genentech ZURICH (AFX) - The US Supreme Court in Washington has ruled that US biotech company MedImmune Inc does not infringe a Genentech Inc production-patent known as Cabilly-II, thus enabling MedImmune to go ahead with its own related lawsuit against Genentech. MedImmune had previously disputed the patent, but had continued to pay royalties to Genentech, which is majority-owned by Swiss pharma group Roche Holding AG. The Cabilly patent is used by MedImmune to make Synagis, a drug that treats childhood respiratory problems. afx.zurich@afxnews.com at/ic
waldron
03/1/2007
09:56
Roche Ag Genentech, Exelixis sign cancer R&D agreement ZURICH (AFX) - Genentech Inc, in which Roche Holding AG holds a majority stake, said it reached a worldwide agreement with Exelixis Inc on the worldwide co-development of XL518, an MEK-inhibitor used in the treatment of tumours. Under the terms of the agreement, Exelixis will receive up-front and milestone payments of around 40 mln usd. Exilixis will be responsible for Phase I development of the inhibitor and will receive further payments should Genentech decide to further pursue the drug's development. afx.zurich@afxnews.com at/jlw
waldron
24/12/2006
11:26
America's 400 Best Big Companies The Best Of The Best Matthew Herper 01.08.07 Drugs & Biotechnology Genentech In the past three years $9 billion (sales) Genentech has launched three new drugs: the $2 billion (sales) cancer treatment, Avastin, Lucentis for macular degeneration ($400 million sales) and a pill, Tarceva, for lung cancer, with sales of $400 million. But the company's biggest success last year came from the breast cancer medicine Herceptin, an old drug for which Chief Executive Arthur Levinson helped lay the groundwork as a Genentech research scientist 26 years ago. In early-stage breast cancer, Herceptin doubles a woman's chances of living cancer free. Those stunning results have nearly tripled the drug's annual sales to $1.3 billion and answer a challenge Levinson says was proffered by Andy Grove: Save lives, don't just extend them for a few months. Over the past five years Genentech's sales have grown at an annualized 33% and earnings at 95%. Genentech must deal with controversy over high drug prices--even with a new price cap Avastin can cost $55,000 a year. Can the company keep up its winning streak? Levinson is focusing on research into diseases where the immune system goes wrong, like rheumatoid arthritis, multiple sclerosis and allergies. Which explains Genentech's decision last November to buy asthma drug maker Tanox for $919 million in cash. http://www.forbes.com/free_forbes/2007/0108/096d.html?partner=rss
maywillow
13/11/2006
08:16
Genentech's MabThera improves rheumatoid arthritis with repeat treatment - trial ZURICH (AFX) - Genentech Inc, in which Basel-based pharma group Roche Holding AG holds a majority stake, announced positive data from new trials with MabThera/Rituxan against rheumatoid arthritis (RA). According to Genentech, the new data presented at the American college of Rheumatology congress shows an improvement in the physical as well as mental improvement in the quality of life of patients treated repeatedly with the drug. RA is one of the most common auto-aggressive diseases, affecting around 21 million people worldwide. afx.zurich@afxnews.com at/jlw
ariane
10/11/2006
05:26
Genentech buys Tanox for $919 million SAN FRANCISCO (AFX) - Genentech Inc. intends to acquire the tiny biotechnology company Tanox Inc. for $919 million in cash, the South San Francisco-based drug maker announced Thursday. The acquisition will help streamline a three-way partnership the two companies share with Novartis AG in the development and commercialization of the asthma-fighting drug Xolair, which was created by Tanox. Once the deal is completed, Genentech no longer will have to make royalty payments to Tanox while receiving such payments from Novartis. Genentech is offering $20 per share for Houston-based Tanox, a premium of 47 percent to that company's closing price of $13.64 on the Nasdaq Stock Market. The stock has traded between $11.55 and $21 over the past 52 weeks. In after hours trading, Genentech's stock fell 20 cents a share to $81.15. Houston-based shares of Tanox rose $5.86, or 43 percent, to $19.50.
grupo guitarlumber
11/10/2006
16:29
Roche Benefits From Genentech Guidance Wednesday, October 11, 2006 6:32:36 AM ET Dow Jones Newswires 0917 GMT [Dow Jones]--Roche (RHHBY) will benefit from Genentech's (DNA) raised EPS guidance, says Kepler Equities. Genetech's 3Q earnings were higher than seen due to strength of Lucentis, even if other drugs were weaker than seen. "3Q results show the benefits of a broad pipeline," Kepler Equities says. Roche (RHHBY) continues to be a strong pick, analyst says, citing an expected boost in Avastin once it's approved for non-small cell lung cancer, which could come already Thursday. Shares +0.1% at CHF220.60. (HJS) http://www.newratings.com/analyst_news/article_1387688.html
grupo guitarlumber
26/9/2006
08:45
Genentech warns cancer drug Avastin patients of rare brain condition link WASHINGTON (AFX) - Genentech Inc, majority owned by Switzerland's Roche Holding AG, has added warnings about a rare brain condition linked to its cancer drug Avastin, the US Food and Drug Administration said on its website. The new label warns patients using the drug about the possibility of developing a rare brain condition, reversible posterior leukoencephalopathy syndrome (RPLS), the FDA said. But Genentech said Avastin studies had shown that less than 0.1 pct of patients taking Avastin had shown RPLS symptoms. The blockbuster's warnings and adverse reactions notice now also includes information about seven reports of patients who developed holes inside the nose called septum perforations, the FDA said. afx.zurich@afxnews.com jmt/vs
waldron
08/8/2006
13:47
Genentech, Genizon sign license agreement for Crohn's disease GeneMap LONDON (AFX) - Genentech Inc has signed an agreement to license Genizon BioSciences's GeneMap of disease-associated genes, generated from a recent study of Crohn's disease patients in the genetically homogenous Quebec Founder Population, the two companies said. The GeneMap will be used to develop new therapeutic products for Crohn's disease. Financial details of the deal were not disclosed. newsdesk@afxnews.com har
grupo guitarlumber
27/6/2006
08:18
Roche declines comment on financial impact of Avastin trial failure BASEL (AFX) - Roche Holdings AG declined to comment on the financial impact of today's abandonment of Phase III clinical trials of Avastin as a first-line treatment for advanced pancreatic cancer. "We don't want to speculate," a spokesman for the Swiss pharma group said. However, pancreatic cancer is a not very common form of the disease compared with colorectal, lung and breast cancer, he noted. Avastin -- jointly developed with Genentech Inc, in which Roche holds a majority stake -- is already approved in the US and Europe for first-line treatment of patients with advanced colorectal cancer. Avastin was filed in the US in April for the most common form of lung cancer and in Japan, also in April, for treatment of advanced colorectal cancer. Most recently, the drug was filed in the US for the treatment of advanced breast cancer. Roche last year recorded Avastin sales of 1.665 bln sfr. afx.zurich@afxnews.com at/vs
ariane
13/6/2006
08:26
Alzheimer's vaccine 'promising' The vaccine was tested on mice A potential DNA vaccine for Alzheimer's disease has produced promising results in mice. In tests it helped cut levels of key amyloid proteins thought to cause the disease by up to 50% in some parts of the brain. And unlike alternative vaccines in development, which use viruses, it produced no side effects. The Japanese study appears in the journal Proceedings of the National Academy of Sciences. This work represents a promising new line of vaccine development Dr Clive Holmes Over-production of amyloid proteins are thought to trigger symptoms of Alzheimer's by forming clumps that litter the brain. Previous studies have shown that it is possible to stimulate the immune system of mice to attack these plaques if they are immunised with amyloid protein. This approach has been tested in preliminary trials on humans, but early results showed that the immune response was too strong, leading to damaging swelling of the brain, as well as plaque destruction. New studies in man are currently underway that hope to mobilise the immune response in a less aggressive manner so that plaques are destroyed, but brain swelling is avoided. Gentle response The latest approach, developed by a team at Tokyo Metropolitan Institute for Neuroscience, works by stimulating the body to produce small amounts of amyloid protein itself. Mice are injected with naked DNA that codes for these proteins, rather than relying on a special virus to get it into the cell. This has the effect of producing a more gentle immune response, and importantly the DNA has also been designed so that it is not capable of replicating itself by incorporating itself into the human genome. In tests, the latest vaccine reduced the deposition of amyloid proteins by between 15.5% and 38.5% compared with untreated mice. Deposition in specific areas of the brain - the cerebral cortex and hippocampus - was reduced 40%-50%. The researchers suggest that DNA vaccines of the type they have produced could provide a cheap and effective strategy for treating Alzheimer's in future. Dr Clive Holmes, of the Alzheimer's Research Trust, said the Toyko study held great promise. He said: "This work represents a promising new line of vaccine development but more research would be needed to see if this could be replicated safely in humans." Dr Susanne Sorensen, of the Alzheimer's Society, agreed that the fact that the vaccine appeared safe was significant. She said: "The findings support the idea that a vaccine is our best hope for fighting this devastating disease for which there is currently no cure." http://news.bbc.co.uk/2/hi/health/5071036.stm
grupo guitarlumber
26/5/2006
08:36
ZURICH (AFX) - Share prices are expected to open markedly higher tracking overnight US and Tokyo gains, and rebounding from sharp losses last week, traders said. In pre-bourse trading, the Swiss Market Index was 92.40 points higher at 7,573.80. On Wednesday, the last trading day ahead of the Ascension day holiday, the SMI closed down 91.14 points or 1.20 pct at 7,481.33, and the SPI was down 65.10 points or 1.10 pct at 5,824.15. COMPANY NEWS -UBS to buy ABN Amro's futures and options business for 386 mln usd -SWX probes ADB for possible breach of disclosure rules -Swisslog says nearly all rights exercised in 73.2 mln sfr capital hike -Roche affiliate Genentech climbs on FDA filing for Avastin -Swiss companies legally obliged to reveal pay of CEOs, directors MARKET NEWS/SENTIMENT -Given a dearth of market-moving corporate news here, trading volumes will likely be thin today ahead of the weekend and the US and UK holidays Monday. Still, the Swiss Market looks set to recoup some of its severe recent losses. afx.zurich@afxnews.com at/cw/ckj/jfr
waldron
02/3/2006
07:28
Novartis files Lucentis for EU approval for wet AMD ZURICH (AFX) - Novartis AG said that its has filed Lucentis for European Union approval for the treatment of neovascular age-related macular degeneration ("wet AMD"), the leading cause of blindness in people over age 60 in the West. Novartis also submitted Lucentis for approval in Switzerland in February. Genentech Inc, which holds marketing rights for the drug in the US and Canada, said earlier this week that the FDA has given the green light for a 6-month priority review. Genentech is majority owned by Roche Holding AG. afx.zurich@afxnews.com scs/lam
waldron
13/2/2006
10:35
Roche Seen Down On Genentech Drug News Monday, February 13, 2006 3:59:05 AM ET Dow Jones Newswires 0744 GMT [Dow Jones] Roche (RHHBY) stock is likely to open lower on news Genentech (DNA), majority-owned by Roche, is temporarily suspending recruitment of patients for Avastin drug trial. "We see a downside potential of 3%-4% short-term, although this is just one of many studies involving Avastin," strategist says. Shares closed at CHF191.90. (MGE) http://www.newratings.com/analyst_news/article_1203686.html
grupo
Chat Pages: 9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
DNA
Doric Nimr..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211016 00:57:56